Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT01420549

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Ache Laboratorios Farmaceuticos S.A. (from the registry)
Registry
  • NCT NCT01420549
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01420549. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-01-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
Acronym
LANCE
Condition
Hypercholesterolemia
Condition
Dyslipidemia
Intervention (Drug)
Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
Intervention (Drug)
Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
Lead sponsor
Ache Laboratorios Farmaceuticos S.A. (class: industry)

Record details

Record id
cardio:ct-nct01420549
Content hash
8605b50b57323b007d1edbb2f3827987d6be75c1641a32f2892ee5b6ad057d20